What is Potent Acid Inhibition, and How Can it be Achieved?
Authors:
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 65 (Supplement) , 13???23-23
Abstract
The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.Keywords
This publication has 81 references indexed in Scilit:
- Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with chronic hepatitis CJournal of Gastroenterology, 2004
- Polymorphism of interleukin-1β affects the eradication rates of Helicobacter pylori by triple therapyClinical Gastroenterology and Hepatology, 2004
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000
- The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pHJournal of Clinical Gastroenterology, 1997
- Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mgEuropean Journal of Gastroenterology & Hepatology, 1997
- Twenty‐four‐hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placeboAlimentary Pharmacology & Therapeutics, 1995
- Evaluation of the Effect of Lansoprazole in Suppressing Acid Secretion Using 24-Hour Intragastric pH MonitoringJournal of Clinical Gastroenterology, 1995
- Determining the Optimal Dose of Lansoprazole Injection by 24-Hour Intragastric pH MonitoringJournal of Clinical Gastroenterology, 1995
- Gastric Acid in VertebratesScandinavian Journal of Gastroenterology, 1992
- The treatment of gastric ulcer with antisecretory drugsDigestive Diseases and Sciences, 1988